This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

What Does the Future Hold for Ionis Pharma’s Obesity Drug FGFR4Rx with Phase 2a Nearing Completion?

Ticker(s): IONS

Who's the expert?

A physician with significant experience treating metabolic disorders or obese patients.

Interview Questions
Q1.

What is your background dealing with metabolic disorders?

Added By: kcmckee
Q2.

What are your initial impressions on IONS obesity drug based on how it performed in Phase 1? What would you expect to see in the Phase 2a data?

Added By: kcmckee
Q3.

Are there any alternative types of obesity treatment you see as more viable (other than exercise)?

Added By: kcmckee
Q4.

Are there any competitors to Ionis you're aware of that may be flying under the radar? How do you see them as a threat?

Added By: kcmckee
Q5.

IONS had two phase 3 trial concerns this year and a huge stock plunge as a result (the drugs may have caused severely depressed platelet counts). Does this have any implications on how you see IONIS-FGFR4Rx performing?

Added By: kcmckee
Q6.

Some analysts have suggested IONS could have trouble getting drugs to market due to its platelet related financial troubles. Are metabolic drugs like IONIS-FGFR4Rx ypically more or less expensive to develop? Do you see this drug as promising enough to attract buyer's for the company?

Added By: kcmckee

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.